Semaglutide Improves Taste Recognition in Women With Obesity and PCOS
In a 16-week randomized study of women with obesity and PCOS, semaglutide improved taste recognition by an estimated 2.5 points versus placebo.
PICO
Structured summariesStructured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
In-Hospital CGM Improves Time in Range in Type 2 Diabetes: DIATEC Trial
In a two-center randomized trial, diabetes-team CGM-guided insulin titration increased inpatient time in range from 62.7% to 77.6% versus point-of-care glucose testing.
AI-Led Diabetes Prevention Program Is Noninferior to Human Coaching
In a phase 3 noninferiority trial, an AI-led Diabetes Prevention Program was noninferior to human coaching for a 12-month composite of weight, physical activity and HbA1c outcomes.
Tirzepatide Added to Basal Insulin Improves Glycemic Control in Type 2 Diabetes
In a 40-week phase 3 trial in China, tirzepatide 10 mg or 15 mg added to basal insulin reduced HbA1c more than placebo, with mainly mild or moderate gastrointestinal events.
Hypoglycemia Prolongs QTc in Type 2 Diabetes and Healthy Adults
A randomized crossover clamp study found that hypoglycemia prolonged QTc, with recovery by 90 minutes after euglycemia and no effect from mineralocorticoid receptor blockade.
Sleep Optimization to Improve Glycemic Targets in Adults With Type 1 Diabetes: A Randomized Controlled Parallel Intervention Trial.
In a Diabetes Care randomized trial, Sleep-Opt did not improve glycemic targets or sleep parameters, although sleep improved in both intervention groups. Key reported results included A1C and CGM parameters at 12 weeks indicated no significant differences between groups.
Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM): A Randomized Controlled Trial in Chinese Patients With Young-Onset Diabetes.
In a Diabetes Care randomized trial, A 3-year technology-enhanced, multicomponent program improved cardiometabolic status, proxies of β-cell function, and PROMs in individuals with YOD but did not reduce complications. Key reported results included During 2020 to 2021, 884 participants (mean [SD]...
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
In a JAMA randomized trial, The authors' conclusion is reported in the source abstract. Key reported results included This predefined subgroup included 3655 patients (1849 in the evolocumab group and 1806 in the placebo group) with a median age of 65 years (57% female).
Ultra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion.
In a Diabetes Care randomized trial, Using URLi in conventional CSII pump therapy provides more effective BRRs prior to exercise compared with lispro, with fewer hypoglycemic events in active adults with type 1 diabetes. Key reported results included Twenty-five participants (mean ± SD age 36.7 ±...
Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly.
In a Diabetes Care randomized trial, Semaglutide significantly improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and promoted substantial weight loss in patients with antipsychotic-induced metabolic disturbances. Key reported results included Participants (56%...